Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00078949
Completed
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
08/03/2023
Locations: Rush-Presbyterian-St. Luke's Medical Centre, Chicago, Illinois +26 locations
Conditions: Lymphoma
Register for Updates
Antibiotic Concentration After Delivery to Middle Ear for Chronic Suppurative Otitis Media
NCT05133258
Completed
The study team aims to elucidate the potential role of ototopical antibiotic concentration on outcomes in patients diagnosed with chronic suppurative otitis media (CSOM). Chronic suppurative otitis media (CSOM) is characterized by chronic inflammation of the middle ear with persistent discharge from a non-intact tympanic membrane. CSOM is notably associated with a significant burden of disease worldwide. Topical fluoroquinolones are first line therapy for CSOM and are advantageous as compared to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2023
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Chronic Suppurative Otitis Media
Register for Updates
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
NCT02906332
Terminated
This is an open-label, Phase II, single center trial of pembrolizumab (MK-3475), lenalidomide and dexamethasone in subjects with high risk Multiple Myeloma (hrMM) post high-dose chemotherapy with autologous stem cell transplantation (ASCT). Patients with high-risk MM defined as those with one of the following abnormalities who have undergone induction therapy followed by single or tandem melphalan -based ASCT will be considered eligible.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/28/2023
Locations: John Theurer Cancer Center-Hackensack Meridian Health, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery
NCT04521140
Completed
Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2023
Locations: Advanced Vision Care, Los Angeles, California
Conditions: Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Register for Updates
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
NCT01850524
Completed
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: Not set, Birmingham, Alabama +147 locations
Conditions: Multiple Myeloma
Register for Updates
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
NCT02592707
Terminated
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of biodistribution, dosimetry and preliminary efficacy of satoreotide tetraxetan.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: MD Anderson Cancer Center, Department of Nuclear Medicine, Houston, Texas +8 locations
Conditions: Neuroendocrine Tumors
Register for Updates
Randomized Open Investigation Determining Steroid Dose
NCT04834375
Completed
Dexamethasone has been approved for the treatment of severe COVID-19, but higher doses of steroids may be more effective. The purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determine if it would be more effective against COVID-19 pneumonia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: Northwell Health, New Hyde Park, New York
Conditions: Covid19
Register for Updates
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
NCT04276090
Terminated
Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy. This study aims to test the safety of hepatic artery infusion pump placement, a standard surgical procedure, and intraarterial chemotherapy initiation with the standard medication floxuridine (FUDR), using the Medtronic Synchromed II pump combined with the Codman arterial catheter in patients with unresectable (not removable by surgery)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Bile Duct Neoplasms, Colorectal Neoplasms
Register for Updates
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients
NCT01749969
Completed
Primary Objectives: * To determine the maximum tolerated dose of SAR650984 (isatuximab) with lenalidomide and dexamethasone (LD) in patients with relapsed or refractory multiple myeloma. * Expansion Phase Only: To further evaluate preliminary evidence of antitumor activity (objective response rate \[ORR\]) of SAR650984 (isatuximab) in combination with LD using International Myeloma Working Group (IMWG) criteria. Secondary Objectives: * To evaluate the safety, including immunogenicity, of SAR6... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: Investigational Site Number 840004, San Francisco, California +4 locations
Conditions: Plasma Cell Myeloma
Register for Updates
The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1
NCT05143281
Completed
To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/05/2023
Locations: Grene Vision Group, Wichita, Kansas +1 locations
Conditions: Cataract
Register for Updates
Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19
NCT04860518
Terminated
This double-blinded, randomized study is being conducted to see if the investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a, can help patients recover more quickly from COVID-19 and prevent worsening of the condition. To understand if IV IFN beta-1a can help treat patients with COVID-19, this study drug will be compared to dexamethasone. Study subjects will be treated daily with IV IFN beta-1a 10 μg or IV dexamethasone for 6 consecutive days whi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2023
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Covid19
Register for Updates
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
NCT04156828
Terminated
This phase I trial studies the best dose of copanlisib when given together with combination chemotherapy (R-GCD) in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or grade 3b follicular lymphoma that has come back (relapsed) after 1 prior line of therapy. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2023
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Register for Updates